Structure–Activity Relationship Studies in a Series of 2-Aryloxy-N-(pyrimidin-5-yl)acetamide Inhibitors of SLACK Potassium Channels
Molecules · 2024
DOI: 10.3390/molecules29235494 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Nigam M Mishra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA. Hauptthemen laut MEDLINE: Acetamides, Potassium Channel Blockers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, National Institute of Neurological Disorders and Stroke.
Abstract (Originalsprache)
Epilepsy of infancy with migrating focal seizures (EIMFS) is a rare, serious, and pharmacoresistant epileptic disorder often linked to gain-of-function mutations in the KCNT1 gene. KCNT1 encodes the sodium-activated potassium channel known as SLACK, making small molecule inhibitors of SLACK channels a compelling approach to the treatment of EIMFS and other epilepsies associated with KCNT1 mutations. In this manuscript, we describe a hit optimization effort executed within a series of 2-aryloxy-N-(pyrimidin-5-yl)acetamides that were identified via a high-throughput screen. We systematically prepared analogs in four distinct regions of the scaffold and evaluated their functional activity in a whole-cell, automated patch clamp (APC) assay to establish structure-activity relationships for wild-type (WT) SLACK inhibition. Two selected analogs were also profiled for selectivity versus other members of the Slo family of potassium channels, of which SLACK is a member, and versus a panel of structurally diverse ion channels. The same two analogs were evaluated for activity versus the WT mouse channel as well as two clinically relevant mutant human channels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, UNT System College of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
- Department of Pharmacology, Vanderbilt University, Nashville, TN 37232, USA.
- Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, TN 37232, USA.
- College of Biomedical and Translational Sciences, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
ORCID-Profile: Nigam M Mishra, Brittany D Spitznagel, Yasmeen K Mohamed, Kyle A Emmitte
Förderung
- NINDS NIH HHS
- NIH HHS
- National Institute of Neurological Disorders and Stroke
- certain funds managed by Deerfield Management Company
- Office of The Director (OD) of the National Institutes of Health
Zitieren
APA
Mishra, N. M., Spitznagel, B. D., Du, Y., Mohamed, Y. K., Qin, Y., Weaver, C. D., & Emmitte, K. A. (2024). Structure–Activity Relationship Studies in a Series of 2-Aryloxy-N-(pyrimidin-5-yl)acetamide Inhibitors of SLACK Potassium Channels. Molecules. https://doi.org/10.3390/molecules29235494
Vancouver
Mishra NM, Spitznagel BD, Du Y, Mohamed YK, Qin Y, Weaver CD, et al. Structure–Activity Relationship Studies in a Series of 2-Aryloxy-N-(pyrimidin-5-yl)acetamide Inhibitors of SLACK Potassium Channels. Molecules. 2024. doi:10.3390/molecules29235494
BibTeX
@article{Mishra2024,
author = {Mishra, Nigam M and Spitznagel, Brittany D and Du, Yu and Mohamed, Yasmeen K and Qin, Ying and Weaver, C David and Emmitte, Kyle A},
title = {Structure–Activity Relationship Studies in a Series of 2-Aryloxy-N-(pyrimidin-5-yl)acetamide Inhibitors of SLACK Potassium Channels},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29235494}
}
EUVIMED